These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 7033992)

  • 1. Treatment of severe essential hypertension with labetalol: effect on active and inactive renin.
    Hauger-Klevene JH
    Pharmatherapeutica; 1981; 3(1):46-54. PubMed ID: 7033992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Essential arterial hypertension. Effects of labetalol on blood pressure and renin-angiotensin system (author's transl)].
    Martinand A; Lardoux H; Corvol P; Milliez P
    Nouv Presse Med; 1980 Sep; 9(35):2565-8. PubMed ID: 7001349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of arterial hypertension with labetalol. A polycentric study].
    G Ital Cardiol; 1982; 12(10):729-35. PubMed ID: 7182212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous labetalol in severe hypertension. Effects on blood pressure, plasma renin activity and catecholamines.
    Lechi A; Picotti GB; Covi G; Pomari S; Pedrolli E; Cesura AM; Danti G; Mattioli M
    Arzneimittelforschung; 1981; 31(3):524-6. PubMed ID: 7013770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Labetalol in resistant hypertension.
    Dargie HJ; Dollery CT; Daniel J
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):751-5. PubMed ID: 990154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of labetalol, a new alpha- and beta-adrenoreceptor blocking drug, on arterial pressure, renal function and renin activity (author's transl)].
    Zech P; Pozet N; Sassard J; Vincent M
    Nouv Presse Med; 1980 Mar; 9(15):1087-90. PubMed ID: 7008020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient].
    Sassard J; Zech PY; Pozet N; Cuisinaud G; Vincent M
    J Pharmacol; 1983; 14 Suppl 2():121-9. PubMed ID: 6355664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension.
    Rasmussen S; Nielsen PE
    Postgrad Med J; 1980; 56 Suppl 2():33-6. PubMed ID: 7433340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.
    Trust PM; Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):799-803. PubMed ID: 791333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute management of severe hypertension with oral labetalol.
    Ghose RR
    Br J Clin Pharmacol; 1979; 8(Suppl 2):189S-193S. PubMed ID: 526400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with labetalol in hypertension.
    Bolli P; Waal-Manning J; Wood AJ; Simpson FO
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):765-71. PubMed ID: 791330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of exercise on intra-arterial blood pressure and pulse rate before and during long-term high-dose treatment with labetalol in patients with severe, therapy-resistant hypertension.
    la Cour Petersen E; Kristensen BO
    Postgrad Med J; 1980; 56 Suppl 2():60-4. PubMed ID: 7433345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Labetalol in severe and resistant hypertension.
    Williams LC; Murphy MJ; Parsons V
    Br J Clin Pharmacol; 1979; 8(Suppl 2):143S-147S. PubMed ID: 526395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interdose control of beta-blockade and arterial blood pressure during chronic oral labetalol treatment.
    Sanders GL; Murray A; Rawlins MD
    Br J Clin Pharmacol; 1979; 8(Suppl 2):125S-127S. PubMed ID: 43163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension.
    Ronne-Rasmussen JO; Andersen GS; Jensen NB; Andersson E
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):805-8. PubMed ID: 990157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled comparison of labetalol and propranolol in the management of severe hypertension.
    Pugsley DJ; Armstrong BK; Nassim MA; Beilin LJ
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):777-82. PubMed ID: 791331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diazoxide vs labetalol: a cross-over comparison of short-term effects in hypertension.
    Rumboldt Z; Bagatin J; Vidovic A
    Int J Clin Pharmacol Res; 1983; 3(1):47-54. PubMed ID: 6679507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre study of labetalol in hypertension. New Zealand Hypertension Study Group.
    N Z Med J; 1981 Apr; 93(681):215-8. PubMed ID: 7017511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effect and plasma levels of labetalol. A comparison with propranolol and dihydrallazine.
    Lehtonen A; Allonen H; Kleimola T
    Int J Clin Pharmacol Biopharm; 1979 Feb; 17(2):71-5. PubMed ID: 422304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypotensive effect of a single daily dose of labetalol: a preliminary study.
    Rossi A; Ziacchi V; Lomanto B
    Int J Clin Pharmacol Ther Toxicol; 1982 Sep; 20(9):438-45. PubMed ID: 6754634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.